Pemvidutide seen to lower liver fat in MASLD patients in Phase 1 trial
August 6, 2024 / MASLD Treatment / Metabolic Dysfunction / Clinical Trial Results
Pemvidutide, an experimental therapy, significantly reduced liver fat, inflammation, and body weight in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) during a Phase 1 trial. A Phase 2b trial is ongoing to further assess its efficacy.
Pennington Biomedical researcher Dr. Carrie Elks awarded $1.4 million to study fat cell communication cycle
August 5, 2024 / Insulin Resistance / OSM / Obesity Treatment / Adipose Tissue
Dr. Carrie Elks received a $1.4 million NIH grant to study insulin resistance and inflammation in fat cells. Her research will focus on the communication loop between fat and immune cells, regulated by Oncostatin M (OSM), to improve obesity treatments.
Diabetes and obesity can damage the liver to the point of failure – but few people know their risk of developing liver disease
August 3, 2024 / Metabolic Dysfunction / Liver Diesase Risk / Insulin Resistance / Obesity
Metabolic dysfunction-associated steatotic liver disease (MASLD), linked to obesity, type 2 diabetes, and insulin resistance, can lead to liver failure and cancer. Early diagnosis and lifestyle changes are crucial for effective management and treatment.
Comparing the Efficacy of HIIT Versus MICT for ObesityBioscience
July 23, 2024 / Obesity Treatment / Body Fat Reduction / Biochemical Markers
A study comparing high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) found HIIT to be more effective in reducing body fat percentage and improving biochemical markers in college students with obesity.
Association between polychlorinated biphenyl (PCB) and dioxin with metabolic syndrome (METS): a systematic review and meta-analysis
August 2, 2024 / PCBs / Dioxin Exposure / Metabolic Syndrome / Diabetes / EDCs
This systematic review and meta-analysis found a strong association between polychlorinated biphenyl (PCB) exposure and diabetes mellitus, with weaker associations between PCBs and other metabolic syndrome risk factors. Dioxin exposure was weakly associated with metabolic syndrome.
Typical Cushing’s symptoms not recognized by patients, study finds
August 2, 2024 / Cushing’s Syndrome / Diagnosis
A study found that patients often fail to recognize typical Cushing’s syndrome symptoms, leading to delayed diagnosis. Physicians identify more symptoms than patients, emphasizing the need for improved awareness and proactive diagnostic measures.
A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma
August 2, 2024 / Metabolic Dysfunction / Helpatocellular Carcinoma / Mouse Model
Researchers developed a male mouse model using streptozotocin and a high-fat diet to study the full spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD), including fatty liver, MASH, fibrosis, and hepatocellular carcinoma (HCC). Tirzepatide showed effectiveness in alleviating these conditions.
Using microphysiological systems to investigate fatty liver disease and drug-induced liver injury (DILI)
August 1, 2024 / MPS / MASLD / Liver Research
Using microphysiological systems (MPS), researchers developed an in vitro model to study fatty liver disease (MASLD) and drug-induced liver injury (DILI). This model mimics human liver conditions, aiding in understanding the mechanisms behind MASLD and DILI.
Study Identifies Most Accurate Noninvasive Method for Diagnosing MASH
August 1, 2024 / MASH Diagnosis / Liver Testing / Metabolic Dysfunction
A study compared three noninvasive methods (MAST, FAST, MEFIB) for diagnosing metabolic dysfunction-associated steatohepatitis (MASH). MAST showed the highest accuracy and predictive performance, potentially offering an effective alternative to invasive liver biopsies.
Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive
August 1, 2024 / GLP-1 Agonists / Metablic Dysfunction / Liver Fibrosis
Combining resmetirom, a liver-targeted THRβ agonist, with GLP-1 agonists may effectively treat metabolic dysfunction-associated steatohepatitis (MASH) by addressing fat accumulation, inflammation, and fibrosis. This complementary approach targets both intrahepatic and extrahepatic mechanisms for improved patient outcomes.
A new cell type to fight obesity
July 31, 2024 / Obesity Treatment / Mesothelial Cells / Metabolic Disorders
Researchers discovered mesothelial cells in omental adipose tissue secreting IGFBP2, which inhibits fat cell formation, potentially offering a new obesity treatment. This highlights the role of adipose tissue heterogeneity in metabolic disorders like type 2 diabetes and cardiovascular diseases.
Epigenetic reprogramming and hypothalamic changes in metabolic syndrome
July 31, 2024 / Metabolic Syndrome / Obesity / Type 2 Diabetes / Dypothalamic Dysfunction / Liver Disease
Metabolic syndrome (MetS) affects 20-25% of the global population, leading to severe diseases and increased mortality. It involves conditions like obesity, type 2 diabetes, and nonalcoholic fatty liver disease, with the hypothalamus playing a crucial role in its development.
Epigenetic reprogramming and hypothalamic changes in metabolic syndrome
July 30, 2024 / Metabolic Syndrome / Obesity / Hypothalamic Changes
Epigenetic reprogramming due to maternal and paternal obesity affects hypothalamic function, contributing to metabolic syndrome (MetS). Changes include inflammation, altered neuronal signaling, and disrupted metabolism, highlighting the hypothalamus’s crucial role in MetS development.
Study reveals curcumin’s antidepressant effects in obese type 2 diabetes patients
July 30, 2024 / Mental Health / Obesity / Type 2 Diabetes / Depression / Clinical Trials
A randomized clinical trial found that curcumin significantly reduced depression severity, improved serotonin levels, and lowered inflammation markers in obese patients with type 2 diabetes (T2DM), highlighting its potential as a therapeutic option for this population.